Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
June 05, 2023
Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
June 01, 2023
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
May 08, 2023
Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference
May 08, 2023
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 28, 2023
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
April 24, 2023
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 14, 2023
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
March 06, 2023
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
February 28, 2023
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
February 21, 2023
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
February 11, 2023
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
